The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1,-4 and-5 in human macrophages: Requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase and phosphoinositide 3-kinase signaling pathways by Ashlin, Timothy Gordon et al.
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a  b  s  t  r  a  c  t
Atherosclerosis  is  an  inﬂammatory  disorder  of  the  vasculature  regulated  by  cytokines.  Amongst  the
cytokines,  IL-33  attenuates  the  development  of  atherosclerosis  in mouse  model  systems  via  several
mechanisms,  including  inhibition  of  macrophage  foam  cell  formation  and  promotion  of  a  Th1  to  Th2
shift.  Proteases  produced  by  macrophages,  such  as matrix  metalloproteinases  and  members  of ADAMTS
(a  disintegrin  and  metalloproteinase  with  thrombospondin  motifs)  family,  play  potential  roles  in  regu-
lating  atherosclerotic  plaque  stability.  Despite  such  importance,  the action  of  IL-33  on  the  expression  of
such  proteases  has not  been  analyzed.  We  have  therefore  investigated  the  effect  of  IL-33  on the  expres-
sion  of ADAMTS-1,  -4  and  -5  in  human  macrophages.  Immunohistochemical  analysis  showed  that  these
three  proteases  were  expressed  in  human  atherosclerotic  lesions,  particularly  by  macrophages  and,  to
a lesser  extent,  by smooth  muscle  cells  and endothelial  cells.  The  expression  of ADAMTS-1,  -4 and  -5 in
human  macrophages  was  speciﬁcally  inhibited  by IL-33.  The  action  of IL-33  on  the  expression  of  these
ADAMTS  members  was  mediated  through  its  receptor  ST2.  IL-33  activated  ERK1/2,  JNK1/2  and  c-Jun,  but
not p38  MAPK  or Akt,  in  human  macrophages.  RNA  interference  assays  using  a combination  of aden-
oviral  encoding  small  hairpin  RNA  and  small  interfering  RNA showed  a requirement  of ERK1/2,  JNK1/2,
c-Jun,  PI3K  and  PI3K,  but not  p38,  in  the IL-33-inhibited  expression  of these  ADAMTS  isoforms.  These
studies  provide  novel  insights  into  the  expression  of  ADAMTS-1,  -4 and -5  in human  atherosclerotic
lesions  and  the  regulation  of their  expression  in  human  macrophages  by the key  anti-atherogenic  cytokine
IL-33.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Abbreviations: ADAMTS, a disintegrin and metalloproteinase with throm-
ospondin motifs; apoE, apolipoprotein E; BMDM,  bone marrow-derived
acrophages; DAB, 3,3′-diaminobenzidine; ECM, extracellular matrix; HMDM,
uman monocyte-derived macrophages; IHC, immunohistochemistry; MMP,
atrix metalloproteinase; RT-qPCR, real-time quantitative PCR; shRNA, small hair-
in RNA; siRNA, small interfering RNA.
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Atherosclerosis, an inﬂammatory disease of the vasculature, is
responsible for most deaths in the western world. Although the
discovery of statins has had a major impact in reducing mortality
from atherosclerosis and its complications, many clinical stud-
ies have highlighted the signiﬁcance of residual cardiovascular
risk in patients on statin therapy (McLaren et al., 2011; Michael
et al., 2012a). It is therefore important to target other risk fac-
tors and to understand the molecular basis of the disease in detail.
Macrophages play a pivotal role in all stages of atherosclerosis,
including the production of proteases that control the remodel-
ing of the extracellular matrix (ECM) and, thereby, plaque stability
(McLaren et al., 2011; Michael et al., 2012a). From these proteases,
 license.
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he role of the matrix metalloproteinase (MMP)  family in atheroge-
esis has been extensively investigated (Newby, 2012). However,
ecent studies are also indicating a potentially important role for
 disintegrin and metalloproteinase with thrombospondin motifs
ADAMTS) family in atherosclerosis (Salter et al., 2010).
The ADAMTS proteases are secreted enzymes able to interact
ith, and degrade, components of the ECM, such as procollagen,
ggrecan, versican, cartilage oligomeric matrix protein, biglycan,
ecorin and ﬁbromodulin (Salter et al., 2010). Recent evidence
uggests important roles for some members in atherosclerosis
nd cardiovascular disease (Salter et al., 2010). For example, sev-
ral ADAMTS members are expressed in atherosclerotic plaques
Jonsson-Rylander et al., 2005; Wagsater et al., 2008; Salter et al.,
010; Lee et al., 2011, 2012; Didangelos et al., 2012). In addition,
enome wide association studies have linked ADAMTS-7 to coro-
ary atherosclerosis and pediatric stroke (Reilly et al., 2011; Arning
t al., 2012). Furthermore, elevated levels of ADAMTS-4 have been
ound in the plasma and peripheral monocytes of patients with
cute coronary syndrome (Zha et al., 2010). Moreover, an associa-
ion between serum ADAMTS-4 levels and the severity of coronary
rtery disease has been observed (Chen et al., 2011).
Because atherosclerosis is an inﬂammatory disorder orches-
rated by cytokines (McLaren et al., 2011; Michael et al., 2012a),
t is important to fully understand their impact on the expression
f the ADAMTS family members. The expression of ADAMTS-4, -7,
8 and -9 mRNA was ﬁrst shown to be induced in macrophages by
he cytokines IFN- or TNF- (Wagsater et al., 2008). In contrast, the
xpression of ADAMTS-1 was inhibited by IFN- (Wagsater et al.,
008). The anti-atherogenic cytokine TGF- inhibited the expres-
ion of ADAMTS-4 in human macrophages and small interfering
NA (siRNA)-mediated knockdown studies identiﬁed important
oles for Smads, p38 MAPK and c-Jun in this response (Salter et al.,
011). However, the effect of other key anti-atherogenic cytokines
n the expression of ADAMTS family in macrophages along with
he underlying mechanisms has not yet been investigated.
IL-33 is a recently characterized member of the IL-1 family of
ytokines and promotes Th2 type immune responses by signaling
hrough the ST2 and IL-1RAcP dimeric receptor complex (Kakkar
nd Lee, 2008). The activation of the ST2 receptor by IL-33 has
een shown to stimulate multiple signaling pathways including
F-B, MAPK and PI3K (Brint et al., 2002; Funakoshi-Tago et al.,
008, 2011; Choi et al., 2009; Tare et al., 2010; Yagami et al.,
010; Kamekura et al., 2012). Recent studies indicate a protec-
ive role for the IL-33-ST2 axis in atherosclerosis (Miller and Liew,
011). Thus, exogenous administration of IL-33 induced a Th1
o Th2 shift within the plaques of an apolipoprotein E (apoE−/−)
ouse model of diet-induced atherosclerosis (Miller et al., 2008).
n addition, injection of IL-33 resulted in signiﬁcantly smaller
therosclerotic lesions compared to vehicle treated controls (Miller
t al., 2008). Furthermore, IL-33 treatment signiﬁcantly reduced the
ccumulation of macrophage-derived foam cells in atherosclerotic
laques (McLaren et al., 2010b). IL-33 also reduced macrophage
oam cell formation in vitro by decreasing acetylated and oxidized
DL uptake, reducing intracellular total and esteriﬁed cholesterol
ontent and enhancing cholesterol efﬂux (McLaren et al., 2010b).
hese changes were associated with IL-33-mediated reduction in
he expression of key genes involved in modiﬁed LDL uptake,
uch as CD36, and simultaneous increase in the expression of
enes involved in cholesterol efﬂux, including apoE (McLaren et al.,
010b). The use of bone marrow-derived macrophages (BMDM)
rom ST2−/− mice demonstrated that this receptor is integral to the
ction of IL-33 on macrophage foam cell formation (McLaren et al.,
010b).
We present here studies on the expression of ADAMTS-1, -4 and
5 within atherosclerotic lesions from human coronary arteries,
nd the effect of IL-33 on their levels in human macrophages. Wehemistry & Cell Biology 46 (2014) 113– 123
demonstrate for the ﬁrst time that IL-33 reduces the expression of
ADAMTS-1, -4 and -5 and this requires the ST2 receptor. In addition,
using a combination of biochemical analysis and RNA interference
assays, we show a requirement for ERK, JNK and PI3K signaling in
the response.
2. Methods
2.1. Reagents
All chemicals were purchased from Sigma–Aldrich (Poole, UK)
unless otherwise stated. Recombinant human and mouse IL-33
were supplied by Peprotech (London, UK).
2.2. Cell culture
The human acute leukemia cell line THP-1 and human
monocyte-derived macrophages (HMDM) were grown in complete
RPMI-1640 supplemented with 10% (v/v) heat-inactivated FCS,
penicillin (100 U/ml), streptomycin (100 g/ml) and l-glutamine
(2 mmol/L) at 37 ◦C in a humidiﬁed atmosphere containing 5%
(v/v) CO2. HMDM were differentiated from monocytes isolated
from buffy coats supplied by the Welsh Blood service using Ficoll-
Hypaque puriﬁcation described elsewhere (McLaren et al., 2010a;
Michael et al., 2012b). THP-1 monocytes were differentiated into
macrophages using 0.16 M PMA  for 24 h. In all experiments,
unless otherwise stated, macrophages were incubated with IL-
33 (10 ng/ml) for 24 h. Recombinant IL-33 was  reconstituted in
PBS/0.1% (w/v) BSA that was subsequently used as a vehicle control.
2.3. Human coronary artery sections
Human coronary artery specimens were collected from cadav-
eric heart donors to the Bristol Coronary Artery Biobank under
National Research Ethics Service approval from Frenchay Research
Ethics Committee reference 08/H0107/48. The left and right coro-
nary arteries were dissected within 48 h of death and pressure ﬁxed
at 100 mmHg  with 4% (v/v) paraformaldehyde for 24 h at 4 ◦C. After
parafﬁn embedding, serial 5 m sections were used for immuno-
histochemistry (IHC) (Huang et al., 2012).
2.4. Real-time quantitative PCR (RT-qPCR)
RNA extraction, reverse transcription and qPCR analysis were
performed as described elsewhere (McLaren et al., 2010a,b;
Michael et al., 2012b). Oligonucleotide sequences are shown in
Supplementary Table I and were purchased from Sigma–Aldrich.
Fold changes in expression were calculated using 2−(Ct1−Ct2),
where Ct represents the difference between the threshold cycle
(Ct) for each target gene and housekeeping mRNA transcript levels
(McLaren et al., 2010a). Melting curve analysis was performed on
each primer set to conﬁrm ampliﬁcation of a single product and all
amplicons were sequenced to ensure reaction speciﬁcity (data not
shown).
2.5. Western blotting
Total cell lysates were size-fractionated and analyzed by west-
ern blotting as previously described (McLaren et al., 2010a,b;
Michael et al., 2012b). Samples were subjected to electrophoresis
alongside comparative molecular weight markers (GE Healthcare,
Wisconsin, USA) to determine the size of the protein product. Anti-
bodies were from Cell Signaling Technologies (Danvers, MA,  USA)
[phospho p44/p42 Thr202/Tyr204 (9101), total p44/p42 (9102),
phospho p38 Thr180/Tyr182 (9211), total p38 (9212), phospho
Akt Ser473 (9271) and total Akt (9272)], Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA) [phospho-c-Jun Ser63 (sc-822) and total
c-Jun (sc-1694)], and Sigma–Aldrich [-actin (A2228)].
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.6. RNA interference
siRNA transfections were carried out using validated siRNAs
gainst human c-Jun (SI00300580), JNK-1 (SI02758637), JNK-2
SI02222920) and ERK-2 (SI00300755) from Qiagen (Manchester,
K). Negative control siRNA (AM4611) was from Invitrogen (Pais-
ey, UK). Stock solutions were prepared from lyophilized siRNAs
ccording to the manufacturer’s instructions (Qiagen and Invitro-
en) and used at a ﬁnal concentration of 7.5 nM.  siRNA transfection
as carried out in THP-1 cells using INTERFERinTM prior to
ifferentiation with 0.16 M PMA  according to the manufac-
urer’s instructions (Polyplus Transfection) (Source Biosciences
ifeSciences, Nottingham, UK) as previously described (Salter et al.,
011; Michael et al., 2012b). Cells were then subjected to cytokine
timulation for the requisite time period before being harvested for
NA extraction.
The production of recombinant adenovirus encoding small hair-
in RNA (shRNA) that target ERK-1 or -2 along with scrambled
equence has been previously described (McLaren et al., 2010a; Li
t al., 2010). A similar approach was used to prepare adenovirus-
ncoding shRNA against p38, PI3K- and - (McLaren et al., 2010a;
i et al., 2010; Michael et al., 2012b) (see Supplementary Table 2
or the oligonucleotide sequences used for the preparation of these
ecombinant viruses). The recombinant virus was  added to the cells
t a multiplicity of infection of 100, as optimized in our previous
tudies (McLaren et al., 2010a; Li et al., 2010; Michael et al., 2012b).
he infection was left for 2.5 h at 37 ◦C, 5% (v/v) CO2, and then
he differentiation performed with 0.16 M PMA. The cells were
ig. 1. IL-33 inhibits the expression of ADAMTS-1, -4 and -5 in human macrophages.
HP-1 macrophages or HMDM were treated for 24 h with vehicle (Control) or 10 ng/ml IL-
DAMTS-1, -4, -5 or GAPDH. The mRNA expression levels were calculated using the compa
ells  given an arbitrary value of 1. Data represent the mean ± SD of 3 independent experi
*P  < 0.05).hemistry & Cell Biology 46 (2014) 113– 123 115
then incubated for 48 h at 37 ◦C, 5% (v/v) CO2, followed by cytokine
stimulation and harvesting for RNA extraction.
2.7. IHC
Serial 5 m parafﬁn sections were de-waxed, rehydrated
and the endogenous peroxidase activity inhibited as previously
described (Scholtes et al., 2012). After rinsing, sections were
heated in 10 mM citrate buffer (pH 6.0) for 2 periods of 6 min.
Following blocking with 20% (v/v) goat serum in PBS, sections
were incubated overnight at 4 ◦C with antibodies against human
ADAMTS-1 (Santa Cruz, sc-25581), ADAMTS-4 (Thermo Fisher Sci-
entiﬁc, PA1-1749) and ADAMTS-5 (Santa Cruz, sc-134952), or an
antibody against human macrophage CD68 (Dako, Cambridgeshire,
UK, PGM1) or human -smooth muscle actin (Dako, 1A4) in
1% (w/v) BSA in PBS. After overnight incubation, sections were
washed and incubated with an appropriate biotinylated secondary
antibody, followed by incubation with extravidin horseradish
peroxidase (Sigma–Aldrich, St Louis, MO)  and stained with 3,3-
diaminobenzidine (DAB) (Sigma–Aldrich). The sections were then
counterstained with hematoxylin, mounted in DPX mountant and
visualized on a light microscope (Leica).
2.8. Statistical analysisAll data are presented as mean (±SD) on the assigned number
of independent experiments where, in experiments involving
HMDM,  this refers to the number of independent experiments
33. Total cellular RNA was isolated and subjected to RT-qPCR using primers against
rative Ct method and normalized to GAPDH with those from control, vehicle-treated
ments. Statistical analysis was performed using Student’s t test or Wilcoxon t-test
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erformed using samples from different donors. Data sets were
ested for normality using the Shapiro–Wilk test. Single compar-
sons of data were carried out using a Student’s t-test (two-tailed,
aired) or Wilcoxen t test. For multiple comparisons one-way
NOVA was mainly used along with Tukey’s post hoc test, where
omogeneity of variance was met, or Welch’s test of equality
f means with Games–Howell post hoc analysis. Results were
egarded as signiﬁcant if P ≤ 0.05.
. Results
.1. ADAMTS-1, -4 and -5 were present in human atherosclerotic
esions and their expression in macrophages was inhibited by
L-33
In order to evaluate whether ADAMTS-1, -4 and -5 were
xpressed in human coronary artery atherosclerotic lesions, IHC
as carried out using antisera against these proteases along with
D68 and -smooth muscle actin (Supplementary Fig. 1). The
se of a negative isotype control antisera showed no background
taining produced by any non-speciﬁc interactions. For -smooth
uscle actin, the DAB staining was concentrated in the ﬁbrous
ap region of the plaque and in the media layer of the coro-
ary artery. The CD68 staining indicated that macrophages and
acrophage foam cells were present in the shoulder regions of
ig. 2. IL-33 activates ERK1/2 and JNK/c-Jun pathways in human macrophages.
HP-1 macrophages were treated for 24 h with vehicle (Control; −) or 10 ng/ml IL-33 (+
ith  antisera against phospho-ERK, -c-Jun, -p38, -Akt; or total-ERK, -c-Jun, -p38 and -Akt
otal  protein and are displayed as fold change with respect to the control (arbitrarily as
ean  ± SD from 3 (ERK, c-Jun and Akt) or 5 (p38) independent experiments. Statistical anhemistry & Cell Biology 46 (2014) 113– 123
the plaque and also in and around the lipid-rich core. ADAMTS-
1, -4 and -5 were all expressed within the human atherosclerotic
lesions. These proteases were mainly expressed by macrophages
and, to a lesser extent, by smooth muscle cells and endothelial
cells.
We next investigated the action of IL-33 on ADAMTS-1, -4
and -5 expression in human macrophages using the extensively
employed THP-1 cell line with key ﬁndings conﬁrmed in primary
cultures of HMDM.  Our previous studies showed that 10 ng/ml IL-
33 inhibited macrophage foam cell formation in vitro (McLaren
et al., 2010b) and this concentration was therefore used for all
experiments. In addition, previous studies have shown that marked
IL-33 dependent modulation of foam cell formation and associ-
ated changes in gene expression occurred at 24 h (McLaren et al.,
2010b) and this time point was  therefore used in the current study.
We have previously shown that IL-33 induces apoE mRNA expres-
sion and this response was  thus used as a positive control for
the action of this cytokine (data not shown). IL-33 produced a
signiﬁcant reduction in the expression of ADAMTS-1, -4 and -5
mRNA in both THP-1 macrophages and primary cultures of HMDM
(Fig. 1). This inhibitory effect of IL-33 was speciﬁc to ADAMTS mem-
bers as the expression of MMP-9 was induced by this cytokine
(Supplementary Figure 2). Further studies on the mechanisms
underlying the actions of IL-33 focused on ADAMTS-1 and -4 as
model genes.
). Equal amounts of total cellular protein were subjected to Western blot analysis
, as indicated. The levels of phospho protein were normalized to the corresponding
signed as 1). A representative image is shown with the histograms indicating the
alysis was performed using Student’s t test (*P < 0.05; NS, not signiﬁcant).
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.2. The IL-33-mediated attenuation of ADAMTS-1 and -4
xpression was dependent on the ST2 receptor
Using RNA puriﬁed from BMDM of wild type and ST2 deﬁcient
ice, we have previously shown that the effect of IL-33 on the
xpression of key genes implicated in the control of macrophage
holesterol homeostasis requires the ST2 receptor (McLaren et al.,
010b). In order to investigate if the ST2 receptor was also involved
n the IL-33-mediated inhibition of ADAMTS-1 and -4 expression,
he same RNA was used for RT-qPCR. As shown in Supplemen-
ary Figure 3, mIL-33 attenuated mADAMTS-1 and -4 expression
n BMDM from wild type mice but not those that were deﬁcient in
T2, thereby indicating a requirement for the ST2 receptor in the
esponse. These data also show that the inhibitory action of IL-33
n the expression of ADAMTS-1 and -4 was conserved between
uman and mouse macrophages.
.3. IL-33 stimulation of human macrophages activated ERK-1/2,
NK-1/2 and c-Jun but not p38 MAPK or AktPrevious studies have shown the involvement of a number of
ignaling pathways in the action of IL-33, including NF-B, MAPK
nd PI3K, though gene- and cell type-speciﬁc differences often exist
ig. 3. ERK1/2 was required for the IL-33-inhibited expression of ADAMTS-1 and -4.
nockdown in THP-1 macrophages was carried out using adenoviral vectors encoding 
reated for 24 h with vehicle (ﬁlled bars) or 10 ng/ml IL-33 (open bars). For mRNA express
RK-1,  -2, ADAMTS-1, -4 or GAPDH. The mRNA expression levels were calculated using
ehicle-treated cells given an arbitrary value of 1. Data represent the mean ± SD of 3 in
***P  < 0.001; **P < 0.01; *P < 0.05; NS, not signiﬁcant). For protein expression, whole cell ly
sing  antibodies against total-ERK and -actin as indicated. The image shown is represenhemistry & Cell Biology 46 (2014) 113– 123 117
(Brint et al., 2002; Funakoshi-Tago et al., 2008, 2011; Choi et al.,
2009; Tare et al., 2010; Yagami et al., 2010; Kamekura et al., 2012).
Initial transient transfection assays with a luciferase reporter vector
containing four NFB consensus binding site (pNFB-Luc) showed
no activation by IL-33 (data not shown). We  then determined the
action of IL-33 on MAPK and PI3K pathways by monitoring the
effect of this cytokine on phosphorylation-dependent activation of
either the kinase itself (ERK and p38) or key downstream targets
(c-Jun for JNK and Akt for PI3K). As shown in Fig. 2, IL-33 produced
a signiﬁcant increase in the levels of phospho-ERK1/2 and -c-Jun
without having an effect on the levels of phospho-p38 and -Akt. In
contrast, the total levels of all these proteins were not affected by
the cytokine. Overall, therefore, these results suggest activation of
the ERK1/2 and JNK/c-Jun signaling pathways by IL-33 in human
macrophages.
3.4. The IL-33-mediated inhibition of ADAMTS-1 and -4
expression was dependent on ERK-1/2, JNK-1/2, c-Jun, PI3K and
PI3Kı but not p38˛The role of the various pathways was investigated with RNA
interference assays using either adenoviral encoding shRNA or val-
idated siRNA. In the case of adenovirus encoding ERK-1 or -2 shRNA,
either a scramble shRNA or ERK-1 shRNA or ERK-2 shRNA. The cells were either
ion, total cellular RNA was isolated and subjected to RT-qPCR using primers against
 the comparative Ct method and normalized to GAPDH with those from control,
dependent experiments. Statistical analysis was  performed using Student’s t test
sates from vehicle-treated cells were subjected to SDS-PAGE and Western blotting
tative of 2 independent experiments.
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Fig. 4. p38 was  not required for the IL-33-inhibited expression of ADAMTS-1 and -4.
Knockdown in THP-1 macrophages was carried out using adenoviral vectors encoding either scramble shRNA or p38. The cells were either treated for 24 h with vehicle
(ﬁlled  bars) or 10 ng/ml IL-33 (open bars). For mRNA expression, total cellular RNA was isolated and subjected to RT-qPCR using primers against p38, ADAMTS-1, -4 or
GAPDH.  The mRNA expression levels were calculated using the comparative Ct method and normalized to GAPDH with those from control, vehicle-treated cells given an
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he  image shown is representative of 2 independent experiments.
T-qPCR showed knockdown of the corresponding RNA by 69% and
4% respectively (Fig. 3). The knockdown was speciﬁc as ERK-2
xpression was not changed by the ERK-1 shRNA, and vice versa,
RK-1 expression was not affected by ERK-2 shRNA (Supplemen-
ary Fig. 4). Consistent with our previous studies (e.g. Michael et al.,
012b), the speciﬁc knockdown of ERK-1 and -2 mRNA expression
as also seen at the level of the corresponding proteins (Fig. 3). The
L-33-mediated reduction in ADAMTS-1 and -4 expression in cells
nfected with a scramble shRNA sequence was attenuated when
he expression of ERK-1 or -2 was knocked down (Fig. 3). Similar
esults were obtained when knockdown experiments were carried
ut using ERK-2 siRNA (Supplementary Fig. 5).
p38 is the most abundant isoform of p38 kinases within inﬂam-
atory cells and has been widely studied in relation to cytokine
ctions (Chung, 2011). As shown in Fig. 4, adenovirus-encoding
38 shRNA produced a signiﬁcant knockdown of the correspond-
ng mRNA by about 90% in THP-1 macrophages. The knockdown
as also conﬁrmed at the level of the protein (Fig. 4). The IL-33-
ediated reduction in ADAMTS-1 and -4 expression in control cells
as not affected following knockdown of p38, thereby indicating
hat this kinase was not required for the response (Fig. 4).
JNK-1 and -2 are key components of the JNK MAPK signaling
athway with c-Jun a major downstream target (Kim and Choi,
010). The roles of JNK-1/2 and c-Jun were investigated by siRNA-
ediated knockdown assays. The expression of JNK-1, -2 and c-Jun
RNA was signiﬁcantly reduced by siRNA transfection by 54%, 45%
nd 38% respectively (Fig. 5). The knockdown of c-Jun was also
onﬁrmed at the level of protein expression (Fig. 5). Consequently,
he IL-33-mediated reduction in ADAMTS-1 and -4 expression was
ttenuated when the cells were transfected with siRNA against
NK-1, -2 or c-Jun siRNA (Fig. 5).
The catalytic p110-  and - subunits of PI3K are expressed by
aematopoietic cells and are activated downstream of G-protein-
oupled receptors, receptor tyrosine kinases and certain cytokinecal analysis was performed using Student’s t test (***P < 0.001;**P < 0.01; *P < 0.05).
-PAGE and Western blotting using antibodies against p38 and -actin as indicated.
receptors (Williams et al., 2010). Adenoviral encoding shRNA
against PI3K and PI3K were used to study their roles in the
IL-33-mediated inhibition of ADAMTS-1 and -4 expression. The
knockdown obtained was  about 91% for PI3K and 86% for PI3K
and this inhibited the IL-33-mediated reduction in ADAMTS-1 and
-4 expression (Fig. 6).
3.5. Conﬁrmation of ﬁndings in primary HMDM
In order to rule out the possibility that the results from RNA
interference assays were peculiar to THP-1 macrophages, key ﬁnd-
ings were conﬁrmed in primary cultures of HMDM.  Because of low
transfection efﬁciency associated with such cultures, adenoviral-
mediated RNA interference assays were performed. The studies
were therefore restricted to ERK1/2, p38 and p110-/ because
of availability of adenoviral shRNA encoding virus. The knock-
down produced was  about 74% for ERK-1, 71% for ERK-2, 66% for
p38, 81% for PI3K and 77% for PI3K (Supplementary Fig. 6). The
speciﬁcity of knockdown was conﬁrmed by representative experi-
ments with ERK-1 and -2 (Supplementary Fig. 6). Similar to THP-1
macrophages, the IL-33-mediated inhibition of ADAMTS-1 and -
4 expression in control HMDM was  diminished with adenoviral
encoding shRNA for ERK-1, ERK-2, PI3K and PI3K but not p38
(Fig. 7).
4. Discussion
Recent studies have suggested a potentially important role for
the ADAMTS family in atherosclerosis (Salter et al., 2010). We  show
here that ADAMTS-1, -4 and -5 were expressed in human coro-
nary artery lesions and their expression in human macrophages
was inhibited by the anti-atherogenic cytokine IL-33. In addition,
we identify important roles for the ERK, JNK and PI3K signaling
pathways in the response.
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Fig. 5. JNK1/2 and c-Jun were required for the IL-33-inhibited expression of ADAMTS-1 and -4.
siRNA-mediated knockdown was carried out using either a scramble siRNA sequence or that against JNK1/2 or c-Jun. The cells were then either treated for 24 h with vehicle
(ﬁlled  bars) or 10 ng/ml IL-33 (open bars). For mRNA expression, total cellular RNA was isolated and subjected to RT-qPCR using primers against JNK-1, -2, c-Jun, ADAMTS-1,
-4,  or GAPDH. The mRNA expression levels were calculated using the comparative Ct method and normalized to GAPDH mRNA with those from control, vehicle-treated cells
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The expression of ADAMTS-1, -4 and -5 was at the highest level
n macrophages and to a lesser extent in vascular smooth muscle
ells and endothelial cells of human atherosclerotic plaques (Sup-
lementary Fig. 1). Interestingly, a recent study has shown elevated
DAMTS-1 expression within plaques from patients with acute
yocardial infarction compared to stable angina (Lee et al., 2011).
n separate studies serum levels of ADAMTS-4 have also shown a
igniﬁcant correlation with the severity of coronary artery disease
Zha et al., 2010; Chen et al., 2011). These ﬁndings, taken together,
utline the potential regulatory role that ADAMTS proteases could
ave over the stability of the atherosclerotic plaque.
We have recently investigated the regulation of expression of
DAMTS-1, -4 and -5 during macrophage differentiation and in
esponse to several other cytokines (Ashlin et al., 2013). The expres-
ion of ADAMTS-1, -4 and -5 was induced during differentiation
f monocytes into macrophages. IL-17 and TL1A alone had little
ffect on the expression of these proteases but induced them syn-
rgistically when present together. In addition, a differential action
as seen with the pro-atherogenic cytokine IFN- and the anti-
therogenic cytokine TGF-. IFN- suppressed the expression of
DAMTS-1 without affecting ADAMTS-4 and -5 whereas TGF-
nduced the expression of ADAMTS-1 and -5 and inhibited that of
DAMTS-4. In contrast to such differential actions, IL-33 attenuated
he expression of all three ADAMTS members (Fig. 1).ts. Statistical analysis was  performed using Student’s t test (***P < 0.001; **P  < 0.01
ed cells were subjected to SDS-PAGE and western blotting using antibodies against
riments.
IL-33 has been found to have a protective role during atheroscle-
rosis development (Miller, 2011). The cytokine promotes Th2
responses, thereby slowing inﬂammation and stabilizing the devel-
oping plaque (Miller and Liew, 2011). In addition, IL-33 reduces
atherosclerosis in apoE−/− mice fed a high fat diet (Miller et al.,
2008). Our data demonstrate that IL-33 reduces the expression of
ADAMTS proteases which have previously been implicated in ECM
remodeling and destabilization of the atherosclerotic plaque (Salter
et al., 2010). We also found that IL-33 increases the expression
of MMP-9 (Supplementary Fig. 2). Normal physiological levels of
MMP-9 expression have previously been implicated with a plaque
stabilizing role during atherosclerosis progression (Newby, 2012).
These data taken together suggest gene speciﬁc regulatory patterns
for IL-33 that results in an anti-atherogenic plaque phenotype.
Of the ADAMTS family of proteases, the promoter regions of
only ADAMTS-4 and -5 have been characterized (Mizui et al., 2000;
Thirunavukkarasu et al., 2006, 2007). We found that the activity
of the available ADAMTS-4 promoter (−383 to +406) was  sup-
pressed by IL-33 (data not shown), thereby indicating that the
cytokine inhibited the expression of this gene, at least in part, at
the transcriptional level. Mizui and colleagues (2000) previously
showed that the −383 to +10 region of the ADAMTS-4 promoter was
required for full promoter activity. This region of the promoter con-
tains one site for Sp1 and three AP-2 sites (Mizui et al., 2000). The
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Fig. 6. p110- and - were required for the IL-33-inhibited expression of ADAMTS-1 and -4.
Knockdown in THP-1 macrophages was carried out using adenoviral vectors encoding either a scramble shRNA or that for p110- or -. The cells were then either treated
for  24 h with vehicle (ﬁlled bars) or 10 ng/ml IL-33 (open bars). Total cellular RNA was  isolated and subjected to RT-qPCR using primers against p110-, -, ADAMTS-1, -4 or
GAPDH. The mRNA expression levels were calculated using the comparative Ct method and normalized to GAPDH mRNA levels with those from control, vehicle-treated cells
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IL-33 has been shown to promote inﬂammation by inducing
ymphocytic inﬁltration in a ST2-independent manner, in vivo
Luzina et al., 2012). It was therefore of interest to determine if
he ST2 receptor was involved in the transduction of the cytokine-
ediated regulation of ADAMTS-1 and -4 gene expression. This
as indeed found to be the case by RT-qPCR analysis of RNA from
MDM of wild type and ST2 receptor-deﬁcient mice (Supplemen-
ary Fig. 3). This ﬁnding is consistent with many other studies that
ave shown that the ST2 receptor is involved in regulation of gene
xpression by IL-33 (Kakkar and Lee, 2008; Miller and Liew, 2011;
uzina et al., 2012).
Several studies have investigated the actions of IL-33 in differ-
nt cell types with some cell- and gene-speciﬁc responses being
dentiﬁed (Brint et al., 2002; Funakoshi-Tago et al., 2008, 2011;
hoi et al., 2009; Tare et al., 2010; Yagami et al., 2010; Kamekura
t al., 2012). For example, p38 MAPK was activated in lung endothe-
ial cells but not epithelial cells (Yagami et al., 2010). In addition,
RK was not activated in the basophil-like chronic myelogenous
eukemia cell line, KU812 (Tare et al., 2010). A previous study in
ouse peritoneal macrophages found IL-33-mediated activation
f ERK, JNK, p38 and NFB (Funakoshi-Tago et al., 2011). It wasts. Statistical analysis was performed using Student’s t test (***P < 0.001; **P < 0.01;
therefore of interest to investigate which signaling cascades were
activated by IL-33 in human macrophages. The use of western blots
and transfection-based assays showed, for the ﬁrst time, IL-33-
mediated activation of ERK and c-Jun/JNK but not Akt and p38
MAPK in human macrophages (Fig. 2). These results differ slightly
from previous studies on mouse peritoneal macrophages where
p38 MAPK was  found to be activated in addition to ERK and JNK
(Funakoshi-Tago et al., 2011). This might potentially reﬂect species-
speciﬁc differences. Indeed, species-speciﬁc responses have been
observed previously during the regulation of macrophage func-
tions by the peroxisome proliferator-activated receptor and liver
X receptor families of transcription factors (Rigamonti et al., 2008).
Also the concentration of IL-33 used on peritoneal macrophages
(100 ng/ml) (Funakoshi-Tago et al., 2011) was  10 fold higher than
that used within this study, which was based on previous dose
response experiments (McLaren et al., 2010b). Indeed, the concen-
tration of 10 ng/ml lies within the physiological range of human
IL-33 levels (can reach up to 40 ng/ml) and has been employed
widely in other in vitro studies (McLaren et al., 2010b).RNA interference assays showed that ERK-1/2, PI3K/ and
JNK/c-Jun were involved in transducing the reduction of ADAMTS-
1 and -4 expression by IL-33, but p38 was not required (Figs. 3–7).
It is worth noting that the ﬁndings in the majority of previous
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Fig. 7. ERK1/2 and p110-/ but not p38 were required for the IL-33-inhibited expression of ADAMTS-1 and -4 in HMDM.
Knockdown in HMDM was  carried out using adenoviral vectors encoding a scramble shRNA or that against ERK-1/-2, p38 or p110-/.  The cells were then either treated
for  24 h with vehicle (ﬁlled bars) or 10 ng/ml IL-33 (open bars). Total cellular RNA was  isolated and subjected to RT-qPCR using primers against ADAMTS-1, -4 or GAPDH. The
mRNA expression levels were calculated using the comparative Ct method and normalized to GAPDH mRNA levels with those from control, vehicle-treated cells given an
arbitrary value of 1. Data represent the mean ± SD of 3 independent experiments. Statistical analysis was  performed using Student’s t test (***P < 0.001; **P < 0.01; *P < 0.05;
NS,  not signiﬁcant).
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tudies that investigated IL-33 signaling in other cell types was
ased mainly on the use of pharmacological inhibitors of the
arious signaling cascades (Brint et al., 2002; Funakoshi-Tago
t al., 2008, 2011; Choi et al., 2009; Tare et al., 2010; Yagami
t al., 2010; Kamekura et al., 2012). Although pharmacological
nhibitors are usually the ﬁrst method of investigation in cell
ignaling pathways, it is important that the ﬁndings are conﬁrmed
y knockdown/knockout approaches due to the associated non-
peciﬁc actions of chemical inhibitors (Cohen P, 2010). The use
f RNA interference enables very speciﬁc knockdown of selected
soforms of proteins with limited off-target effects (Eggert et al.,
006), as demonstrated here in the case of ERK-1 and -2 (Fig. 3).
he requirement of ERK-1/2 and c-Jun/JNK was associated with the
ctivation of the corresponding kinase/protein (Fig. 2). However,
he requirement of PI3K- and - was independent of the activation
f one of its key downstream targets, Akt (Fig. 2). This suggests that
argets other than Akt were potentially involved in the response.
. Conclusion
The data presented here demonstrate for the ﬁrst time that
he anti-atherogenic cytokine IL-33 attenuates the expression of
DAMTS-1, -4 and -5 in human macrophages. The mechanism of
ignal transduction was dependent on ST2 binding, ERK-1, ERK-2,
-Jun, JNK-1, JNK-2, PI3K and PI3K. Further studies, which are
eyond the scope of the present manuscript, would be to delin-
ate how these signaling pathways modulate the action of key
ranscription factors involved in inhibiting the expression of these
DAMTS members. In addition, the therapeutic implications of this
tudy extend to IL-33 being identiﬁed as a potential therapeutic tar-
et for modulating the expression of ADAMTS-1, -4 and -5 during
therosclerotic plaque development.
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